Author: Overseas Sales Dept. Publish Time: 2026-10-13 Origin: Site
JIABO PHARMA successfully concluded its European debut at CPHI Milan 2026, held from October 6–8 at Fiera Milano, Italy.
During the three-day exhibition, our team connected with pharmaceutical partners and industry professionals from Europe, the Middle East, Latin America, and other markets, exchanging insights and exploring new opportunities for collaboration.
Integrated Solutions for Perioperative Care
JIABO PHARMA offers a growing portfolio of injectable products covering key areas of perioperative care, including anesthesia, analgesia, neuromuscular blockade, and postoperative nutritional support. Our integrated capabilities in R&D, API manufacturing, and finished dosage production support product development and regulatory collaboration with partners worldwide.
Quality, Supply, and Global Partnerships
With over two decades of experience in propofol, JIABO PHARMA combines in-house propofol API manufacturing with finished dosage production, supported by CEP certification for its propofol API and an annual production capacity exceeding 100 million units of propofol injection. Our EU GMP certification reinforces our commitment to international quality standards and provides a solid compliance foundation for entering markets regulated by Stringent Regulatory Authorities.
CPHI Milan 2026 marked an important milestone in our global journey. The exhibition generated encouraging interest in our product portfolio and manufacturing capabilities, while face-to-face discussions helped advance ongoing projects.
Thank you to everyone who connected with us in Milan. JIABO PHARMA looks forward to building lasting partnerships and growing together with customers worldwide.
Event Details
CPHI Milan 2026 | October 6–8, 2026
Fiera Milano, Rho, Italy | Stand 6H71
